India has rapidly emerged as a pivotal hub for Global Capability Centres (GCCs) in the life sciences sector, with nearly half of the world’s top 50 life sciences companies establishing their presence in the country over the past five years. This transformation is detailed in a recent report by EY India titled “Reimagining Life Sciences GCCs,” which highlights the evolution of these centres from mere back-office support units to strategic engines that drive innovation and operational excellence across various domains, including drug discovery, regulatory affairs, and commercial operations.
The shift in the role of GCCs in India reflects a broader trend in the global life sciences landscape. Traditionally, these centres were viewed primarily as cost-saving mechanisms, providing essential administrative support functions such as finance, human resources, and IT. However, the current narrative emphasizes India’s growing importance in the global research and development (R&D) pipeline. As Arindam Sen, partner and GCC Sector Lead at EY India, aptly puts it, “This isn’t about cost arbitrage anymore; it’s about India becoming indispensable to the global R&D pipeline.”
The report underscores that Indian life sciences GCCs are now managing integrated functions that span clinical trials, pharmacovigilance, supply chain analytics, biostatistics, and enabling services like finance, HR, IT, and data analytics. The statistics presented in the report are striking: GCCs in India handle 70% of finance, 75% of HR, 62% of supply chain, and 67% of IT functions for their global firms. Furthermore, core functions have experienced significant growth, with increases of 45% in drug discovery, 60% in regulatory affairs, 54% in medical affairs, and 50% in commercial operations.
Several factors contribute to India’s ascent as a GCC powerhouse. First and foremost is the robust policy support from both central and state governments, which has created a conducive environment for foreign investment and innovation. This policy framework is complemented by a strong talent pool of over 2.7 million life sciences professionals, making India an attractive destination for multinational corporations seeking skilled labor.
Moreover, the country boasts a mature ecosystem that includes Contract Research Organizations (CROs), universities, and startups, all of which play a crucial role in fostering innovation and collaboration. The availability of scalable Grade-A office spaces further enhances India’s appeal as a GCC location, providing the necessary infrastructure for companies to establish and expand their operations.
As these GCCs evolve, they are increasingly positioning themselves as “twins” of their global headquarters. This concept signifies a deeper integration of operations, where Indian centres co-own innovation and accelerate outcomes alongside their parent companies. This collaborative approach not only enhances efficiency but also fosters a culture of innovation that is vital for staying competitive in the fast-paced life sciences industry.
Looking ahead, the future capabilities of these GCCs will be defined by their ability to adapt to changing market dynamics and technological advancements. The report emphasizes the importance of operating model transformation and the need to build agile, multi-disciplinary teams skilled in emerging areas such as generative AI, bioinformatics, and digital health. These skills will be essential for driving the next phase of growth and ensuring that India remains at the forefront of life sciences innovation.
The implications of this transformation extend beyond the corporate realm. As India solidifies its position as a global leader in life sciences GCCs, it also stands to benefit from increased investment in research and development, leading to advancements in healthcare and pharmaceuticals. This, in turn, can enhance patient outcomes and contribute to the overall well-being of society.
Furthermore, the establishment of GCCs in India presents opportunities for knowledge transfer and capacity building within the local workforce. As multinational companies bring their expertise and best practices to India, they also contribute to the development of local talent, creating a virtuous cycle of growth and innovation. This synergy between global firms and local professionals is crucial for fostering a sustainable ecosystem that can respond to the evolving needs of the life sciences sector.
In conclusion, the rise of life sciences GCCs in India represents a significant shift in the global landscape of pharmaceutical and biotechnology industries. With nearly half of the world’s top life sciences companies setting up operations in the country, India is poised to become a critical player in the global R&D pipeline. The evolution of these centres from back-office support to strategic hubs of innovation underscores the importance of India in shaping the future of life sciences. As the country continues to invest in its talent pool, infrastructure, and policy frameworks, it is well-positioned to lead the charge in advancing healthcare solutions and driving meaningful change in the industry.
The journey of India as a GCC hub is just beginning, and the potential for growth and innovation is immense. By embracing new technologies and fostering a culture of collaboration, India can not only enhance its standing in the global life sciences arena but also contribute significantly to improving health outcomes worldwide. The future looks bright for India’s life sciences sector, and the ongoing evolution of GCCs will undoubtedly play a pivotal role in this exciting journey.